194 related articles for article (PubMed ID: 9148009)
1. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
Vogels BA; Karlsen OT; Mass MA; Boveé WM; Chamuleau RA
J Hepatol; 1997 Jan; 26(1):174-82. PubMed ID: 9148009
[TBL] [Abstract][Full Text] [Related]
2. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy.
Vogels BA; van Steynen B; Maas MA; Jörning GG; Chamuleau RA
J Hepatol; 1997 Feb; 26(2):387-95. PubMed ID: 9059962
[TBL] [Abstract][Full Text] [Related]
3. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.
Rose C; Michalak A; Pannunzio P; Therrien G; Quack G; Kircheis G; Butterworth RF
Metab Brain Dis; 1998 Jun; 13(2):147-57. PubMed ID: 9699922
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate.
Albrecht J; Hilgier W; Januszewski S; Quack G
Metab Brain Dis; 1996 Sep; 11(3):229-37. PubMed ID: 8869943
[TBL] [Abstract][Full Text] [Related]
5. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
7. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
Rose C; Michalak A; Rao KV; Quack G; Kircheis G; Butterworth RF
Hepatology; 1999 Sep; 30(3):636-40. PubMed ID: 10462368
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels.
Gebhardt R; Beckers G; Gaunitz F; Haupt W; Jonitza D; Klein S; Scheja L
J Pharmacol Exp Ther; 1997 Oct; 283(1):1-6. PubMed ID: 9336301
[TBL] [Abstract][Full Text] [Related]
9. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.
Vogels BA; Maas MA; Daalhuisen J; Quack G; Chamuleau RA
Hepatology; 1997 Apr; 25(4):820-7. PubMed ID: 9096582
[TBL] [Abstract][Full Text] [Related]
10. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
[TBL] [Abstract][Full Text] [Related]
11. An orally deliverable ornithine-based self-assembling polymer nanomedicine ameliorates hyperammonemia in acetaminophen-induced acute liver injury.
Ding Y; Koda Y; Shashni B; Takeda N; Zhang X; Tanaka N; Nishikawa Y; Nagasaki Y
Acta Biomater; 2023 Sep; 168():515-528. PubMed ID: 37433359
[TBL] [Abstract][Full Text] [Related]
12. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
13. A 15N NMR study of in vivo cerebral glutamine synthesis in hyperammonemic rats.
Kanamori K; Parivar F; Ross BD
NMR Biomed; 1993; 6(1):21-6. PubMed ID: 8096147
[TBL] [Abstract][Full Text] [Related]
14. Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment--results of a pilot study.
Delcker A; Turowski B; Mihm U; Raab P; Rusch O; Pilatus U; Zeuzem S; Zanella FE
Metab Brain Dis; 2002 Jun; 17(2):103-11. PubMed ID: 12083335
[TBL] [Abstract][Full Text] [Related]
15. Selective alterations of extracellular brain amino acids in relation to function in experimental portal-systemic encephalopathy: results of an in vivo microdialysis study.
Rao VL; Audet RM; Butterworth RF
J Neurochem; 1995 Sep; 65(3):1221-8. PubMed ID: 7643101
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute hyperammonemia on cerebral amino acid metabolism and pHi in vivo, measured by 1H and 31P nuclear magnetic resonance.
Fitzpatrick SM; Hetherington HP; Behar KL; Shulman RG
J Neurochem; 1989 Mar; 52(3):741-9. PubMed ID: 2563756
[TBL] [Abstract][Full Text] [Related]
17. Effects of ornithine aminotransferase inactivation by 5-fluoromethylornithine in rats following portacaval anastomosis.
Therrien G; Sarhan S; Knödgen B; Butterworth RF; Seiler N
Metab Brain Dis; 1994 Sep; 9(3):211-24. PubMed ID: 7838064
[TBL] [Abstract][Full Text] [Related]
18. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
[TBL] [Abstract][Full Text] [Related]
19. Organ Distribution of
Cruz NF; Dienel GA; Patrick PA; Cooper AJL
Neurochem Res; 2017 Jun; 42(6):1683-1696. PubMed ID: 27822667
[TBL] [Abstract][Full Text] [Related]
20. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design.
Staedt U; Leweling H; Gladisch R; Kortsik C; Hagmüller E; Holm E
J Hepatol; 1993 Nov; 19(3):424-30. PubMed ID: 8151104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
